Key Insights

Highlights

Treatment Research

1 treatments under study, led by Lorlatinib

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 2 (1)

Trial Status

Completed1

Clinical Trials (1)

Showing 1 of 1 trials
NCT03505554Phase 2Completed

A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma

Showing all 1 trials

Research Network

Common Treatments

  • Lorlatinib1

Active Sponsors

  • Pfizer1
  • University of Milano Bicocca1

Top Investigators

Related Conditions

  • Anaplastic Large Cell Lymphoma Alkpositive1

Activity Timeline